《美國心臟雜志》作為心臟病學家和全科醫(yī)生的可靠資源已有70多年的歷史。現(xiàn)在，在新編輯的領導下，該雜志已重新調整其內容，以響應心臟病學社區(qū)的信息需求。除了發(fā)表重要的臨床調查結果，該雜志還討論了諸如成本效益、臨床試驗設計、陰性臨床試驗報告和不斷變化的醫(yī)療組織等主題。一個新功能- AHJ在會議上報告主要心血管會議的關鍵發(fā)現(xiàn)，為讀者提供了最新的臨床研究數(shù)據(jù)。在4625種最常被引用的科學期刊(科學引文索引)中，《美國心臟雜志》排名前3.7%，在世界范圍內受到廣泛閱讀和尊重。《美國心臟雜志》將考慮發(fā)表與心血管疾病這一廣泛學科相關的合適文章。我們的目標是為讀者提供關于心血管醫(yī)學實踐的初步調查、學術評論和意見。我們特別鼓勵提交三種在心血管雜志上不常見的報告:負面臨床研究、研究設計報告和涉及醫(yī)療組織的研究。本雜志不接受個別病例報告或涉及實驗室或動物研究的原創(chuàng)文章。

American Heart Journal has been a trusted resource for cardiologists and general practice physicians for more than 70 years. Now under new editorship, the Journal has refocused its content to respond to the information needs of the cardiology community. In addition to publishing results of important clinical investigations, the Journal addresses such topics as cost-effectiveness, design of clinical trials, reports of negative clinical trials, and the changing organization of medical care. A new feature - AHJ at the Meetings - reports the key findings from major cardiovascular meetings, providing readers with ready access to the most recent clinical research data. Read and respected throughout the world, American Heart Journal ranks in the top 3.7% of the 4,625 scientific journals most frequently cited ( Science Citation Index ).The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.